United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $235.35, for a total value of $847,260.00. Following the transaction, the chief executive officer now owns 130 shares of the company's stock, valued at $30,595.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Stock Up 8.9 %

UTHR stock traded up $20.81 during mid-day trading on Wednesday, reaching $255.14. The company had a trading volume of 1,410,621 shares, compared to its average volume of 452,774. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. The company has a market capitalization of $12.01 billion, a price-to-earnings ratio of 12.86 and a beta of 0.52. The firm has a fifty day simple moving average of $234.62 and a 200 day simple moving average of $228.81. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same quarter last year, the company earned $2.67 EPS. United Therapeutics's revenue for the quarter was up 25.1% compared to the same quarter last year. Analysts forecast that United Therapeutics Co. will post 23.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Trust Inc. raised its position in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company's stock worth $114,000 after acquiring an additional 46 shares in the last quarter. Formidable Asset Management LLC raised its position in shares of United Therapeutics by 1.5% during the 3rd quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company's stock worth $821,000 after acquiring an additional 53 shares in the last quarter. Alaska Permanent Fund Corp raised its position in shares of United Therapeutics by 1.7% during the 3rd quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company's stock worth $752,000 after acquiring an additional 57 shares in the last quarter. MBM Wealth Consultants LLC raised its position in shares of United Therapeutics by 2.7% during the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company's stock worth $515,000 after acquiring an additional 59 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of United Therapeutics by 1.6% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company's stock worth $856,000 after acquiring an additional 61 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Analysts Set New Price Targets

UTHR has been the topic of several research reports. Wedbush reissued an "outperform" rating and set a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Leerink Partnrs reissued an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, April 11th. HC Wainwright reissued a "buy" rating and set a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, The Goldman Sachs Group raised United Therapeutics from a "sell" rating to a "neutral" rating and increased their target price for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.